Skip to main content
Aptabio Therapeutics Inc. logo

Aptabio Therapeutics Inc. — Investor Relations & Filings

Ticker · 293780 ISIN · KR7293780003 KO Manufacturing
Open in API
Filings indexed 209 across all filing types
Latest filing 2021-11-29 Regulatory Filings
Country KR South Korea
Listing KO 293780

About Aptabio Therapeutics Inc.

https://aptabio.com/

Aptabio Therapeutics Inc. is a biopharmaceutical company dedicated to developing first-in-class drugs for intractable diseases with high unmet medical needs. The company's research is driven by proprietary platform technologies. One core platform focuses on regulating oxidative stress through selective NOX (NADPH oxidase) inhibitors, targeting the root causes of inflammation and fibrosis to treat diabetic complications, vascular diseases, and neurodegenerative disorders. A second platform centers on the regulation of cancer-associated fibroblasts (CAF) to overcome resistance and enhance the efficacy of immuno-oncology therapies for difficult-to-treat cancers. By leveraging these distinct approaches, Aptabio aims to discover and advance novel therapeutic candidates for challenging medical conditions.

Recent filings

Filing Released Lang Actions
기타경영사항(특허권취득)(자율공시)(신규한 피라졸 유도체)
Regulatory Filings Classification · 100% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent ('특허권 취득') by Aptabio. It details the patent name, content, and utilization plan. Since it is a regulatory announcement of a specific corporate event that does not fit into financial reporting, dividend, or management change categories, it falls under the general regulatory filing category.
2021-11-29 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a short announcement regarding an upcoming Investor Relations (IR) event (기업설명회). It provides the date, time, location (online), and purpose of the meeting. It does not contain the actual presentation slides or detailed financial data, but rather serves as a notification of the event's occurrence. According to the 'Menu vs Meal' rule, an announcement of an event or report is classified as a Report Publication Announcement (RPA) or a general regulatory filing. Given the specific nature of announcing an IR event, RPA is the most appropriate classification.
2021-11-16 Korean
분기보고서 (2021.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Aptabio Co., Ltd., covering the period from January 1, 2021, to September 30, 2021. It contains detailed financial information, business operations, management discussions, and research and development activities, which are characteristic of an interim/quarterly financial report. It is not an announcement of a report, but the report itself. 9M 2021
2021-11-15 Korean
기타경영사항(특허권취득)(자율공시)(3-페닐-4-프로필-1-(피리딘-2-일)-1H-피라졸-5-올 염산염의 신규 결정형 고체화합물)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Aptabio regarding the acquisition of a patent for a new crystalline solid form of a chemical compound. It is filed as a 'voluntary disclosure' (자율공시) under the category of 'Other Management Matters' (기타 경영사항). Since this document does not fit into specific categories like financial reports, dividends, or M&A, and is a standard regulatory announcement of a corporate event, it falls under the 'Regulatory Filings' (RNS) category.
2021-10-14 Korean
기타경영사항(특허권취득)(자율공시)(조영제 유발 급성 신부전 치료제)
Regulatory Filings Classification · 100% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent for a contrast-induced acute kidney injury treatment by Aptabio. It does not fit into financial reporting categories like 10-K or IR, nor is it a report publication announcement. As it is a specific regulatory disclosure regarding company operations and intellectual property that does not fall into the other specialized categories, it is classified as a general regulatory filing.
2021-09-29 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service (Korea). This is a standard regulatory filing used by company insiders (directors/major shareholders) to disclose changes in their shareholdings. In the provided classification schema, this falls under 'Director's Dealing' (DIRS), which covers reports of personal share transactions by company directors and executives.
2021-08-25 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.